

sanofi



T1D - TZIELD®

ESR Areas of Interest

June 2026



T1D/Teplizumab areas of interest for ESR

Disease / Screening

- **T1D Epidemiology and patient pathways** (in case of specific local need)
- **Defining the risk of T1D**
- **T1D screening/monitoring and educational initiatives** in at-risk populations
- **Predictive factors of progression through T1D stages** (including characterization of Stage 1 Fast Progressors)
- **C-peptide in clinical practice**

Teplizumab

- **Short- and long-term clinical outcomes with teplizumab across stages**
- **Documenting the clinical outcomes of teplizumab in specific populations**
- **User / HCP experience and patient pathways**
- **Patients' characteristics and biomarkers of response to teplizumab by Stage of T1D**